Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
QLTI-08. THE COLUMBIA NEURO-ONCOLOGY RESEARCH DASHBOARD: A WEB-BASED TOOL TO ASSESS CLINICAL TRIAL RECRUITMENT AND ACCRUAL METRICS
1
Zitationen
7
Autoren
2023
Jahr
Abstract
Abstract BACKGROUND Insufficient trial participation is a recognized barrier to drug development. Research has focused on patient and physician-associated factors, yet few institutions assess the impact of trial availability, referral patterns, and patient eligibility. Screening logs provide a rough estimate of candidate pools but tell us nothing about patients who are not screened, let alone why. To better understand site-specific barriers and effectively assess efforts to overcome them, real-time, data-driven metrics are essential. METHODS To address this need, we created The Columbia Neuro-Oncology Clinical Research Dashboard (CRD), a web-based tool designed to capture all patients presenting to our faculty practice with newly diagnosed or recurrent CNS tumors and track their participation -- or lack thereof -- in interventional trials. From 7/2022 - 9/2022, we experimented with several iterations of the CRD, adjusting the platform and variables in response to user feedback. To pilot the final design, we started with a limited sample of high-grade glioma patients seen at Columbia University Irving Medical Center's Neuro-Oncology Faculty Practice from 9/1/2022 - 1/1/2023. During this period, 62 patients were tracked, allowing for further refinements to improve functionality and data capture. When populated, the CRD was easily queried for important quality improvement metrics including accrual rates, time from presentation to study initiation and grounds for screen failure. It also captured the percentage of patients who were not offered a trial and the cited reasons. Inclusion of demographics and referral patterns provided additional dimensions to the data. NEXT STEPS: The CRD has met its preliminary aims. It provides a user friendly and accessible interface for data capture. With appropriate staffing and implementation processes in place, it has real potential to inform our efforts to improve patient accrual and diversity with real-time metrics. Subsequent efforts will focus on these aspects of the project.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 28.834 Zit.
TNM Classification of Malignant Tumours
1987 · 16.123 Zit.
A survey on deep learning in medical image analysis
2017 · 13.528 Zit.
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.749 Zit.
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
2010 · 9.104 Zit.